ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1105

Allopurinol Dose Escalation to Achieve Serum Urate below 6mg/Dl: An Open Label Extension Study

Lisa K. Stamp1, Peter T. Chapman2, Murray Barclay3, Anne Horne4, Christopher Frampton1, Paul Tan5, Jill Drake6 and Nicola Dalbeth5, 1University of Otago, Christchurch, New Zealand, 2Christchurch Hospital, Christchurch, New Zealand, 3Medicine, University of Otago, Christchurch, New Zealand, 4Department of Medicine, University of Auckland, Auckland, New Zealand, 5University of Auckland, Auckland, New Zealand, 6Rheumatology, Immunology and Allergy, Christchurch Hospital, Christchurch, New Zealand

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Allopurinol and gout

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 6, 2017

Title: Metabolic and Crystal Arthropathies Poster I

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Allopurinol at higher than CrCL based doses remains controversial due to concerns over increased risk of adverse events (AE). A recent 12month randomized controlled trial (RCT) reported that allopurinol above CrCL-based doses is effective and well tolerated. Here, we report the results of the 12month open label extension phase of this RCT. The aims were to determine the long-term safety and efficacy of allopurinol dose escalation to achieve target serum urate (SU) in people with gout.

Methods: People who completed the first 12months of a randomized, controlled, parallel-group, comparative clinical trial continued into a 12month open label extension study (from Month 12 to 24). Participants randomised to the control group who continued their usual dose of allopurinol for the first 12months began allopurinol dose escalation at month 12 if SU was ≥6mg/dl (control (C)/dose escalation (DE)). Those in the DE arm for the first 12months who had achieved target SU maintained the dose of allopurinol, while those with SU≥6mg/dl continued dose escalation (DE/DE). Allopurinol was increased monthly until SU was <6mg/dl. The primary endpoints were reduction in SU and AEs at month 24. Secondary endpoints included the proportion of individuals with gout flares.

Results:  Of the 183 participants who entered the study, 143 (78.1%) completed the month 12 visit and 137 (74.9%) completed month 24. The mean (SE) change in SU from month 12 to month 24 was -1.1 (0.2) mg/dl in the C/DE group and 0.1 (0.2) mg/dl in the DE/DE group (p<0.001) with a mean difference of 1.3mg/dl (95%CI 0.8-1.7), p<0.001). In the C/DE group mean (SE) SU was 7.13 (0.16) mg/dl at baseline and 5.7 (0.2) mg/dl at final visit, and 7.18 (0.2) mg/dl and 5.4 (0.1) mg/dl in the DE/DE group (Fig). SU was <6mg/dl at final visit in 69.1% of the C/DE group and 79.7% in the DE/DE group (p=0.16); odds ratio (OR) 1.8 (95%CI 0.8-3.8). There was a significant reduction in the percentage of individuals having a gout flare in the month prior to month 12 and month 24 in both groups (p<0.001), but no difference between randomised groups (p=0.29). There were similar numbers of AEs and serious AEs between groups. Mild elevations of AST, ALT and ALP were noted while some higher grade abnormalities in GGT were observed.

Conclusion: The majority of people with gout can achieve and maintain target SU with dose escalation of allopurinol above CrCL-based doses. Higher doses of allopurinol are well tolerated.


Disclosure: L. K. Stamp, Amgen, 8; P. T. Chapman, None; M. Barclay, None; A. Horne, None; C. Frampton, None; P. Tan, None; J. Drake, None; N. Dalbeth, Takeda, AstraZeneca, Abbvie, 9.

To cite this abstract in AMA style:

Stamp LK, Chapman PT, Barclay M, Horne A, Frampton C, Tan P, Drake J, Dalbeth N. Allopurinol Dose Escalation to Achieve Serum Urate below 6mg/Dl: An Open Label Extension Study [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/allopurinol-dose-escalation-to-achieve-serum-urate-below-6mgdl-an-open-label-extension-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/allopurinol-dose-escalation-to-achieve-serum-urate-below-6mgdl-an-open-label-extension-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology